期刊文献+

系统性硬化症的主要发病因素及治疗研究进展 被引量:5

The Research Progress in Main Pathogenesis Factors and Treatment of Systemic Sclerosis
原文传递
导出
摘要 系统性硬化症在临床上较为罕见,也被称为硬皮病,属于免疫性疾病的一种,临床上一般根据患者发病后皮肤损伤情况将系统性硬化症分为局限性系统性硬化症、弥漫性系统性硬化症、重叠综合征、无硬化系统性硬化症、未分化结缔组织疾病。通过分析系统性硬化症患者的主要发病原因探讨其应对的治疗措施。系统性硬化症的发病率容易受环境因素、遗传因素的影响,且引起系统性硬化症的环境因素及遗传因素具有多样性,由于系统性硬化症的发病机制尚不清楚,因此临床上治疗系统性硬化症患者仍然存在较大的困难。目前治疗方向主要包括皮肤病变治疗、系统性硬化症的雷诺现象、系统性硬化症的肺部治疗。 Systemic sclerosis is relatively rare in the clinic and is also called scleroderma.It is a type of immune disease.Clinically,systemic sclerosis is generally divided into localized systemic sclerosis and diffuse systemic sclerosis,overlap syndrome,non-sclerotic systemic sclerosis,undifferentiated connective tissue disease.By analyzing the main causes of systemic sclerosis,the author explore the treatment measures.The results showed the onset of systemic sclerosis is easily affected by environmental factors and genetic factors,and the environmental and genetic factors that cause systemic sclerosis are diverse.Because the pathogenesis of systemic sclerosis is unclear,clinically treated patients still have greater difficulties.The current treatment directions include skin lesion treatment,Raynaud’s phenomenon of systemic sclerosis,and pulmonary treatment of systemic sclerosis.
作者 李小芬 韦夙 王乐 杨有国 莫丽丹 江浩 郑玉萍 廖红丽 LI Xiao-fen;WEI Su;WANG Le;YANG You-guo;MO Li-dan;JIANG Hao;ZHENG Yu-ping;LIAO Hong-li(Department of Rheumatology and Immunology,Liuzhou People's Hospital,Guangxi 545006,China)
出处 《药物生物技术》 CAS 2020年第4期390-392,共3页 Pharmaceutical Biotechnology
关键词 系统性 硬化症 发病因素 硬皮病 治疗进展 相关因素 Systemic Sclerosis Pathogenesis Scleroderma Treatment progress Related factors
  • 相关文献

参考文献5

二级参考文献37

  • 1林禾.强的松、青霉胺联合治疗早期系统性硬化症[J].福建医科大学学报,2000,34(S1):99-100. 被引量:2
  • 2吴东海.系统性硬化病诊治指南(草案)[J].中华风湿病学杂志,2004,8(6):377-379. 被引量:26
  • 3于慧敏,张凤山.系统性硬化症发病机制研究进展[J].中华风湿病学杂志,2005,9(6):362-365. 被引量:13
  • 4Chifflot H,Fautzi B,Sorder C,et al.Incidence and prevalence of systemic sclerosis:a systematic literature review[J].Semin Arthritis Rheum,2008,37(4):223-235.
  • 5Derk CT,Huaman G,Jimenez SA.A retrospective randomly selected cohort study of D-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset[J].Br J Dermatol,2008,158(5):1063-1068.
  • 6Khanna D,Furst DE,Hays RD,et al.Minimally important difference in diffuse systemic sclerosis:results from the D-penicillamine study[J].Ann Rheum Dis,2006,65(10):1325-1329.
  • 7DENTON CP. Systemic sclerosis: from pathogenesis to targeted therapy [J]. Clinical and experimental rheumatology, 2015,33 (4 Suppl 92) :S3-7.
  • 8LEFEVRE G, DAUCHET L, HACHULLA E, et al. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis [J]. Arthritis and rheumatism, 2013,65(9) :2412-2423.
  • 9VAN DEN HOOGEN F, KHANNA D, FRANSEN J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative [J]. Annals of the rheumatic diseases, 2013,72( 11 ) : 1747-1755.
  • 10Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events : final report of the pooling project. The pooling project research group [ J ]. J Chronic Dis, 1978,31 (4) : 201-306.

共引文献18

同被引文献71

引证文献5

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部